Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A

Immunogenicity of therapeutic recombinant immunotoxins

(2016) Ronit Mazor et al.   IMMUNOLOGICAL REVIEWS

Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo

(2015) Ronit Mazor et al.   Cellular & Molecular Immunology

Advances in Anticancer Immunotoxin Therapy

(2015) C. Alewine et al.   ONCOLOGIST

Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results

(2015) Emily Mason-Osann et al.   Scientific Reports

An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies

(2014) Tapan K. Bera et al.   LEUKEMIA RESEARCH

In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

(2014) K. Hollevoet et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers

(2014) C. Alewine et al.   MOLECULAR CANCER THERAPEUTICS

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

(2014) R. Mazor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface

(2013) Z. Tang et al.   MOLECULAR CANCER THERAPEUTICS

Influence of tumour micro-environment heterogeneity on therapeutic response

(2013) Melissa R. Junttila et al.   NATURE

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

(2013) R. Hassan et al.   Science Translational Medicine

A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity

(2012) J. E. Weldon et al.   MOLECULAR CANCER THERAPEUTICS

Strategies for extended serum half-life of protein therapeutics

(2011) Roland E Kontermann   CURRENT OPINION IN BIOTECHNOLOGY

A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

(2011) John E. Weldon et al.   FEBS Journal

Hypoxia enhances cancer cell invasion through relocalization of the proprotein convertase furin from the trans-golgi network to the cell surface

(2011) Dominique Arsenault et al.   JOURNAL OF CELLULAR PHYSIOLOGY

RosettaRemodel: A Generalized Framework for Flexible Backbone Protein Design

(2011) Po-Ssu Huang et al.   PLoS One

A novel high-affinity human monoclonal antibody to mesothelin

(2010) Mitchell Ho et al.   INTERNATIONAL JOURNAL OF CANCER

A Recombinant Immunotoxin Targeting CD22 With Low Immunogenicity, Low Nonspecific Toxicity, and High Antitumor Activity in Mice

(2010) Johanna K. Hansen et al.   JOURNAL OF IMMUNOTHERAPY

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity

(2008) J. E. Weldon et al.   BLOOD

Pseudomonas exotoxin A: From virulence factor to anti-cancer agent

(2008) Philipp Wolf et al.   INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY